SG Americas Securities LLC Takes Position in Emergent Biosolutions, Inc. (EBS)

SG Americas Securities LLC acquired a new stake in Emergent Biosolutions, Inc. (NYSE:EBS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,999 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Riverhead Capital Management LLC increased its position in shares of Emergent Biosolutions by 102.8% during the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 587 shares during the period. First Quadrant L P CA purchased a new position in shares of Emergent Biosolutions during the third quarter valued at about $157,000. Meeder Asset Management Inc. increased its position in shares of Emergent Biosolutions by 94.7% during the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 2,302 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of Emergent Biosolutions during the third quarter valued at about $191,000. Hedge funds and other institutional investors own 88.44% of the company’s stock.

Several brokerages recently issued reports on EBS. Wells Fargo & Company reiterated an “outperform” rating and set a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research note on Wednesday, October 25th. Finally, BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $46.00.

In related news, Chairman Fuad El-Hibri sold 47,983 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the sale, the chairman now owns 1,550,216 shares of the company’s stock, valued at $64,923,046.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $39.50, for a total transaction of $311,457.50. Following the sale, the executive vice president now directly owns 33,931 shares in the company, valued at approximately $1,340,274.50. The disclosure for this sale can be found here. Insiders have sold 280,989 shares of company stock worth $11,700,343 in the last three months. 16.50% of the stock is currently owned by insiders.

Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at $46.59 on Friday. Emergent Biosolutions, Inc. has a 52 week low of $27.94 and a 52 week high of $47.37. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37. The company has a market cap of $1,931.09, a PE ratio of 24.68, a P/E/G ratio of 1.34 and a beta of 1.24.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. Emergent Biosolutions’s quarterly revenue was up 4.6% on a year-over-year basis. analysts expect that Emergent Biosolutions, Inc. will post 1.58 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “SG Americas Securities LLC Takes Position in Emergent Biosolutions, Inc. (EBS)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/23/sg-americas-securities-llc-takes-position-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit